Evidence map›Paper›PMID 38830665›Full record

ArticleSaudi medical journal2024

Efficacy of denosumab treatment for lung metastasis secondary to proximal humerus chondroblastoma.

Ramy Samargandi, Mathilde Bernard, Elodie Miquelestorena-Standley, Louis Romée Le Nail

Abstract readCase Reports
In one paragraph

Article in Saudi medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ramy SamargandiFrom the Department of Orthopedic Surgery and Traumatology (Samargandi, Bernard, Le Nail); from the Department of pathology (Miquelestorena-Standley), Tours Regional University Hospital, Tours, France, and from the Department of Orthopedic Surgery (Samargandi), Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.ORCID https://orcid.org/0000-0002-7198-8365
Mathilde BernardFrom the Department of Orthopedic Surgery and Traumatology (Samargandi, Bernard, Le Nail); from the Department of pathology (Miquelestorena-Standley), Tours Regional University Hospital, Tours, France, and from the Department of Orthopedic Surgery (Samargandi), Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.
Elodie Miquelestorena-StandleyFrom the Department of Orthopedic Surgery and Traumatology (Samargandi, Bernard, Le Nail); from the Department of pathology (Miquelestorena-Standley), Tours Regional University Hospital, Tours, France, and from the Department of Orthopedic Surgery (Samargandi), Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.
Louis Romée Le NailFrom the Department of Orthopedic Surgery and Traumatology (Samargandi, Bernard, Le Nail); from the Department of pathology (Miquelestorena-Standley), Tours Regional University Hospital, Tours, France, and from the Department of Orthopedic Surgery (Samargandi), Faculty of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chondroblastoma is a rare benign cartilaginous tumor that accounts for approximately 1% of bone tumors, but it can be associated with lung metastasis in extremely rare cases, leading to a poor prognosis and death. Herein, we report the case of a 19-year-old male patient who presented with an aggressive chondroblastoma of the proximal humerus and bilateral lung metastasis. The patient was treated with wide local resection, partial metastasectomy, and denosumab. Denosumab treatment was effective in controlling metastatic progression and preventing local recurrence.

Indexed as

Bone NeoplasmsChondroblastomaDenosumabHumerusLung NeoplasmsBone Density Conservation AgentsHumansMaleYoung AdultBone Density Conservation AgentsDenosumabbone tumorschondroblastomadenosumabmetastasisRANKRANK-L

Identifiers

PMID38830665
PMCPMC11147590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.